Alvotech to Report Financial Results for H1 2026

Alvotech (NASDAQ: ALVO; ALVO-SDB) will release its financial results for the first half of 2026 on Wednesday, August 19, 2026, after the U.S. market close.

Rhea-AI Summary

Alvotech (NASDAQ: ALVO; ALVO-SDB) will release its financial results for the first half of 2026 on Wednesday, August 19, 2026, after the U.S. market close.

The company will host a webcast with live Q&A on Thursday, August 20, 2026, at 08:00 ET (12:00 GMT, 13:00 BST, 14:00 CEST). Registration links are provided for both the webcast and Q&A, and presentation materials will be available on alvotech.com/financials before the call.

Argus Aug 10 session 2 alerts

-1.05% close to close 0.6x rel. volume Open Argus

Details

News Market Reaction – ALVO

$1.29B Market Cap

On Aug 10, the day this news came out, ALVO closed 1.05% below the previous close. Our momentum scanner recorded 2 alerts for this stock that day.

Data tracked by StockTitan Argus for the Aug 10 session.

Market Context

The tag-specific record covered 2 prior earnings-date notices with an average move of 1.19%. That hi...

Analysis

The tag-specific record covered 2 prior earnings-date notices with an average move of 1.19%. That history adds context without results; investors can compare the scheduled release with reported figures and existing financing risks.

Key Figures

Reporting period: H1 2026 Results release date: August 19, 2026 Webcast date: August 20, 2026 +1 more

Reporting period

H1 2026

Financial results to be released

Results release date

August 19, 2026

After the U.S. market close

Webcast date

August 20, 2026

Live Q&A scheduled

Webcast time

08:00 ET

August 20, 2026

Previous Earnings date Reports

2 past events · Latest: Apr 24

Same Type 2 events

1. Apr 24

   Q1 earnings date

   24h Move

   +0.0%

   Scheduled first-quarter results release and webcast with live Q&A

2. Mar 04

   FY earnings date

   24h Move

   +2.4%

   Scheduled fourth-quarter and full-year results release with conference call

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

biosimilar medicines

1 terms

biosimilar medicines medical

"specializing in the development and manufacture of biosimilar medicines"

Biosimilar medicines are follow‑on versions of complex biological drugs made from living cells that are highly similar to an original approved biologic but not exact copies, like a near‑identical twin rather than a factory‑made duplicate. They matter to investors because they increase competition and typically lower prices for high‑cost therapies, which can reduce revenue for original drugmakers while creating new market opportunities for companies that develop and sell biosimilars.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REYKJAVIK, ICELAND (August 10, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its financial results for the first half of 2026 on Wednesday, August 19, 2026, after the U.S. market close.

The Company will also host a webcast with a live Q&A on Thursday, August 20, 2026, at 08:00 ET (12:00 GMT, 13:00 BST, 14:00 CEST).

• To listen to the webcast, please register here: H1 2026 webcast
• To participate in the Q&A, please register here: Q&A registration

Slides and other materials will be made available on alvotech.com/financials before the call.

For further information, contact:

Media
Benedikt Stefansson
Sarah MacLeod
alvotech.media@alvotech.com

Investors
Dr. Balaji V Prasad (US)
Benedikt Stefansson (IS)
alvotech.ir@alvotech.com

About Alvotech
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China and other Asian countries, and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com.

For more information, please visit our website or follow us on social media on LinkedIn, Facebook, Instagram and YouTube.

None of the information on the Alvotech website shall be deemed part of this press release.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Alvotech (NASDAQ: ALVO) report its H1 2026 financial results?

Alvotech will release its H1 2026 financial results on Wednesday, August 19, 2026, after the U.S. market close. According to Alvotech, these results will cover the first half of 2026 and precede a webcast and Q&A session.

What time is the Alvotech (ALVO) H1 2026 earnings webcast on August 20, 2026?

The Alvotech H1 2026 webcast with live Q&A is scheduled for 08:00 ET on Thursday, August 20, 2026. According to Alvotech, this corresponds to 12:00 GMT, 13:00 BST, and 14:00 CEST to accommodate international investors.

How can investors register for the Alvotech (ALVO) H1 2026 webcast and Q&A?

Investors can register through separate links for the H1 2026 webcast and the Q&A registration provided by Alvotech. According to Alvotech, registration is required to listen to the webcast and to participate in the live Q&A session.

Where will Alvotech (ALVO) provide slides and materials for the H1 2026 results call?

Slides and other materials for the H1 2026 results call will be available on alvotech.com/financials. According to Alvotech, these materials will be posted before the webcast to support investors’ review of the half-year financial results.

Who are the investor relations contacts for Alvotech (NASDAQ: ALVO) regarding H1 2026 results?

Investor inquiries can be directed to Dr. Balaji V Prasad (US) and Benedikt Stefansson (IS) via alvotech.ir@alvotech.com. According to Alvotech, separate media contacts are available at alvotech.media@alvotech.com for press-related questions.

Is the Alvotech (ALVO) H1 2026 webcast open to international investors?

Yes, the Alvotech H1 2026 webcast is scheduled with multiple time zone references for global access. According to Alvotech, the event time is given in ET, GMT, BST, and CEST to support international investors and analysts.